Instem is a robust and profitable provider of IT applications and technology enabled services to life sciences R&D.  Instem helps clients to bring life enhancing products to market faster, with the potential for significant return on their investment.

Instem’s solutions are essential to over 400 clients worldwide in areas such as:

· Collection, analysis and reporting of complex scientific data· Compliance with regulatory submission requirements, including the FDA-mandated SEND initiative· Improving quality, consistency and efficiency of critical R&D processes and corresponding information             reporting· Generating new scientific insights through identification, extraction and analysis of actionable information

Instem anticipates continued organic and acquisitive growth in a buoyant life sciences industry.

ReNeuron is a leading, clinical-stage cell therapy development business.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. 

ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.

Safestay PLC is the owner operator of a branded contemporary “boutique” hostel group. The first Hostel in the Elephant and Castle, London was opened in June 2012.The Safestay Business operates a new brand of contemporary hostel, designed to appeal to a broad range of guests. Known as a “boutique hostel” within the travel industry, it is aimed at providing safe, stylish accommodation which offers a more attractive alternative to both traditional hostels and budget hotel accommodation.

Aus­tralian Secu­ri­ties Exchange listed Scot­gold Resources Lim­ited (ASX:SGZ) was estab­lished in 2007 and listed on the ASX in Jan­u­ary 2008. The company’s shares were admit­ted to trad­ing on the AIM mar­ket of the Lon­don Stock Exchange (AIM:SGZ) in Feb­ru­ary 2010. The Company’s prin­ci­pal objec­tive, since 2008, has been the advance­ment of the Conon­ish Gold and Sil­ver Project in Scotland’s Grampian High­lands to a pro­duc­tion deci­sion and explo­ration of the highly prospec­tive ten­e­ments com­pris­ing the Grampian Gold Project with the view of iden­ti­fy­ing fur­ther project opportunities.

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs.

Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers.

The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow.

A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.